Which has better earnings & valuation, IOVA or AGMB?

AgomAb Therapeutics has lower revenue, but higher earnings than Iovance Biotherapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Iovance Biotherapeutics $285.61M 6.74 -$390.98M -$0.95 N/A AgomAb Therapeutics N/A N/A N/A N/A N/A

Does the media refer more to IOVA or AGMB?

In the previous week, Iovance Biotherapeutics and Iovance Biotherapeutics both had 4 articles in the media. AgomAb Therapeutics' average media sentiment score of 0.40 beat Iovance Biotherapeutics' score of 0.00 indicating that AgomAb Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AgomAb Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, HCM or AGMB?

HUTCHMED has higher revenue and earnings than AgomAb Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED $548.51M 3.64 $456.91M N/A N/A AgomAb Therapeutics N/A N/A N/A N/A N/A

Is HCM or AGMB more profitable?

Company Net Margins Return on Equity Return on Assets HUTCHMED N/A N/A N/A AgomAb Therapeutics N/A N/A N/A

Does the media favor HCM or AGMB?

In the previous week, AgomAb Therapeutics had 1 more articles in the media than HUTCHMED. MarketBeat recorded 4 mentions for AgomAb Therapeutics and 3 mentions for HUTCHMED. AgomAb Therapeutics' average media sentiment score of 0.40 beat HUTCHMED's score of 0.00 indicating that AgomAb Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AgomAb Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, AGMB or NBTX?

AgomAb Therapeutics has higher earnings, but lower revenue than Nanobiotix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A N/A N/A N/A Nanobiotix $36.87M 52.72 -$27.11M N/A N/A

Is AGMB or NBTX more profitable?

Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A Nanobiotix N/A N/A N/A

Which has better valuation and earnings, AGMB or BHC?

Bausch Health Cos has higher revenue and earnings than AgomAb Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A N/A N/A N/A Bausch Health Cos $10.53B 0.17 $157M -$3.24 N/A

Does the media favor AGMB or BHC?

In the previous week, AgomAb Therapeutics had 2 more articles in the media than Bausch Health Cos. MarketBeat recorded 4 mentions for AgomAb Therapeutics and 2 mentions for Bausch Health Cos. AgomAb Therapeutics' average media sentiment score of 0.40 beat Bausch Health Cos' score of 0.20 indicating that AgomAb Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bausch Health Cos 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, SRPT or AGMB?

AgomAb Therapeutics has lower revenue, but higher earnings than Sarepta Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sarepta Therapeutics $2.20B 0.93 -$713.41M -$0.96 N/A AgomAb Therapeutics N/A N/A N/A N/A N/A

Does the media refer more to SRPT or AGMB?

In the previous week, Sarepta Therapeutics had 3 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 7 mentions for Sarepta Therapeutics and 4 mentions for AgomAb Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.79 beat AgomAb Therapeutics' score of 0.40 indicating that Sarepta Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AgomAb Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

AgomAb Therapeutics (AGMB) Competitors

$12.65 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$12.65 0.00 (0.00%)

As of 07/2/2026 04:10 PM Eastern

Compare

AGMB vs. IOVA, HCM, NBTX, BHC, and SRPT

Should you buy AgomAb Therapeutics stock or one of its competitors? MarketBeat compares AgomAb Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AgomAb Therapeutics include Iovance Biotherapeutics (IOVA), HUTCHMED (HCM), Nanobiotix (NBTX), Bausch Health Cos (BHC), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry.

How does AgomAb Therapeutics compare to Iovance Biotherapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

Iovance Biotherapeutics presently has a consensus price target of $8.43, indicating a potential upside of 95.56%. AgomAb Therapeutics has a consensus price target of $32.75, indicating a potential upside of 158.89%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe AgomAb Therapeutics is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

AgomAb Therapeutics has lower revenue, but higher earnings than Iovance Biotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$285.61M	6.74	-$390.98M	-$0.95	N/A
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 7.8% of Iovance Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Iovance Biotherapeutics and Iovance Biotherapeutics both had 4 articles in the media. AgomAb Therapeutics' average media sentiment score of 0.40 beat Iovance Biotherapeutics' score of 0.00 indicating that AgomAb Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AgomAb Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AgomAb Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -123.92%. AgomAb Therapeutics' return on equity of 0.00% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%
AgomAb Therapeutics	N/A	N/A	N/A

Summary

AgomAb Therapeutics beats Iovance Biotherapeutics on 6 of the 10 factors compared between the two stocks.

How does AgomAb Therapeutics compare to HUTCHMED?

HUTCHMED (NASDAQ:HCM) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

8.8% of HUTCHMED shares are held by institutional investors. 3.6% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, AgomAb Therapeutics had 1 more articles in the media than HUTCHMED. MarketBeat recorded 4 mentions for AgomAb Therapeutics and 3 mentions for HUTCHMED. AgomAb Therapeutics' average media sentiment score of 0.40 beat HUTCHMED's score of 0.00 indicating that AgomAb Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AgomAb Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
AgomAb Therapeutics	N/A	N/A	N/A

HUTCHMED has higher revenue and earnings than AgomAb Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$548.51M	3.64	$456.91M	N/A	N/A
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A

HUTCHMED presently has a consensus price target of $16.80, suggesting a potential upside of 46.85%. AgomAb Therapeutics has a consensus price target of $32.75, suggesting a potential upside of 158.89%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe AgomAb Therapeutics is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

AgomAb Therapeutics beats HUTCHMED on 5 of the 9 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Nanobiotix?

AgomAb Therapeutics (NASDAQ:AGMB) and Nanobiotix (NASDAQ:NBTX) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Nanobiotix	N/A	N/A	N/A

38.8% of Nanobiotix shares are held by institutional investors. 3.5% of Nanobiotix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

AgomAb Therapeutics has higher earnings, but lower revenue than Nanobiotix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A
Nanobiotix	$36.87M	52.72	-$27.11M	N/A	N/A

AgomAb Therapeutics presently has a consensus target price of $32.75, suggesting a potential upside of 158.89%. Nanobiotix has a consensus target price of $37.33, suggesting a potential downside of 2.78%. Given AgomAb Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe AgomAb Therapeutics is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, AgomAb Therapeutics had 4 more articles in the media than Nanobiotix. MarketBeat recorded 4 mentions for AgomAb Therapeutics and 0 mentions for Nanobiotix. AgomAb Therapeutics' average media sentiment score of 0.40 beat Nanobiotix's score of 0.00 indicating that AgomAb Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
AgomAb Therapeutics	Neutral
Nanobiotix	Neutral

Summary

AgomAb Therapeutics beats Nanobiotix on 4 of the 7 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Bausch Health Cos?

AgomAb Therapeutics (NASDAQ:AGMB) and Bausch Health Cos (NYSE:BHC) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Bausch Health Cos has higher revenue and earnings than AgomAb Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A
Bausch Health Cos	$10.53B	0.17	$157M	-$3.24	N/A

78.7% of Bausch Health Cos shares are held by institutional investors. 20.7% of Bausch Health Cos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, AgomAb Therapeutics had 2 more articles in the media than Bausch Health Cos. MarketBeat recorded 4 mentions for AgomAb Therapeutics and 2 mentions for Bausch Health Cos. AgomAb Therapeutics' average media sentiment score of 0.40 beat Bausch Health Cos' score of 0.20 indicating that AgomAb Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bausch Health Cos	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

AgomAb Therapeutics presently has a consensus price target of $32.75, suggesting a potential upside of 158.89%. Bausch Health Cos has a consensus price target of $8.00, suggesting a potential upside of 62.44%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe AgomAb Therapeutics is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

AgomAb Therapeutics has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. AgomAb Therapeutics' return on equity of 0.00% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Bausch Health Cos	-11.47%	-2,922.77%	5.63%

Summary

AgomAb Therapeutics beats Bausch Health Cos on 7 of the 11 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Sarepta Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and AgomAb Therapeutics (NASDAQ:AGMB) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

AgomAb Therapeutics has lower revenue, but higher earnings than Sarepta Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.93	-$713.41M	-$0.96	N/A
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A

In the previous week, Sarepta Therapeutics had 3 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 7 mentions for Sarepta Therapeutics and 4 mentions for AgomAb Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.79 beat AgomAb Therapeutics' score of 0.40 indicating that Sarepta Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AgomAb Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

86.7% of Sarepta Therapeutics shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

AgomAb Therapeutics has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -2.94%. Sarepta Therapeutics' return on equity of 7.56% beat AgomAb Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.94%	7.56%	2.94%
AgomAb Therapeutics	N/A	N/A	N/A

Sarepta Therapeutics currently has a consensus price target of $24.81, suggesting a potential upside of 28.68%. AgomAb Therapeutics has a consensus price target of $32.75, suggesting a potential upside of 158.89%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe AgomAb Therapeutics is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.08
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Sarepta Therapeutics beats AgomAb Therapeutics on 8 of the 11 factors compared between the two stocks.

Get AgomAb Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGMB vs. The Competition

Export

Metric	AgomAb Therapeutics	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$458.40M	$538.08M	$5.20B	$12.48B
Dividend Yield	N/A	N/A	16.11%	6.52%
P/E Ratio	N/A	N/A	23.91	24.70
Price / Sales	N/A	388.95	171.59	98.05
Price / Cash	N/A	N/A	35.06	57.09
Price / Book	N/A	2.94	13.25	6.46
Net Income	N/A	-$81.71M	$113.80M	$337.01M
7 Day Performance	-8.40%	7.17%	0.93%	1.69%
1 Month Performance	27.52%	21.82%	1.08%	3.81%
1 Year Performance	N/A	-72.26%	10.03%	23.90%

AgomAb Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGMB AgomAb Therapeutics	N/A	$12.65 flat	$32.75 +158.9%	N/A	$458.40M	N/A	N/A	62
IOVA Iovance Biotherapeutics	1.8607 of 5 stars	$4.16 -1.2%	$8.43 +102.6%	+145.7%	$1.88B	$263.50M	N/A	500	Analyst Revision Gap Down
HCM HUTCHMED	2.9963 of 5 stars	$10.79 +0.7%	$16.80 +55.7%	-28.0%	$1.87B	$548.51M	N/A	1,796	News Coverage
NBTX Nanobiotix	1.8799 of 5 stars	$37.70 +4.8%	$37.33 -1.0%	+666.5%	$1.82B	$36.87M	N/A	100	Short Interest Increase
BHC Bausch Health Cos	2.5055 of 5 stars	$4.93 +1.5%	$8.00 +62.4%	-29.1%	$1.81B	$10.27B	N/A	20,300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGMB) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AgomAb Therapeutics (AGMB) Competitors

AGMB vs. IOVA, HCM, NBTX, BHC, and SRPT

How does AgomAb Therapeutics compare to Iovance Biotherapeutics?

Summary

How does AgomAb Therapeutics compare to HUTCHMED?

Summary

How does AgomAb Therapeutics compare to Nanobiotix?

Summary

How does AgomAb Therapeutics compare to Bausch Health Cos?

Summary

How does AgomAb Therapeutics compare to Sarepta Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGMB vs. The Competition

AgomAb Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AgomAb Therapeutics (AGMB) Competitors

AGMB vs. IOVA, HCM, NBTX, BHC, and SRPT

How does AgomAb Therapeutics compare to Iovance Biotherapeutics?

Do analysts rate IOVA or AGMB?

Which has better earnings & valuation, IOVA or AGMB?

Do institutionals & insiders have more ownership in IOVA or AGMB?

Does the media refer more to IOVA or AGMB?

Is IOVA or AGMB more profitable?

Summary

How does AgomAb Therapeutics compare to HUTCHMED?

Do insiders & institutionals hold more shares of HCM or AGMB?

Does the media favor HCM or AGMB?

Is HCM or AGMB more profitable?

Which has preferable earnings and valuation, HCM or AGMB?

Do analysts rate HCM or AGMB?

Summary

How does AgomAb Therapeutics compare to Nanobiotix?

Is AGMB or NBTX more profitable?

Do insiders and institutionals have more ownership in AGMB or NBTX?

Which has higher valuation and earnings, AGMB or NBTX?

Do analysts rate AGMB or NBTX?

Does the media prefer AGMB or NBTX?

Summary

How does AgomAb Therapeutics compare to Bausch Health Cos?

Which has better valuation and earnings, AGMB or BHC?

Do institutionals and insiders hold more shares of AGMB or BHC?

Does the media favor AGMB or BHC?

Do analysts prefer AGMB or BHC?

Is AGMB or BHC more profitable?

Summary

How does AgomAb Therapeutics compare to Sarepta Therapeutics?

Which has preferable valuation & earnings, SRPT or AGMB?

Does the media refer more to SRPT or AGMB?

Do institutionals & insiders have more ownership in SRPT or AGMB?

Is SRPT or AGMB more profitable?

Do analysts recommend SRPT or AGMB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGMB vs. The Competition

AgomAb Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools